Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.921
-0.021 (-2.19%)
Nov 21, 2024, 11:24 AM EST - Market open
Xilio Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Xilio Therapeutics stock has a target of 4.00, which predicts an increase of 334.50% from the current stock price of 0.92.
Analyst Consensus: Buy
Analyst Ratings
According to 1 stock analyst, the rating for XLO is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +334.50% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +660.37% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +660.37% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +986.25% | Jan 27, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +660.37% | Dec 21, 2022 |
Financial Forecast
Revenue This Year
6.25M
Revenue Next Year
33.06M
from 6.25M
Increased by 428.64%
EPS This Year
-1.27
from -2.78
EPS Next Year
-0.58
from -1.27
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 11.8M | 78.8M | 78.8M | ||
| Avg | 6.3M | 33.1M | 29.5M | ||
| Low | 2.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 1,159.2% | 138.2% | ||
| Avg | - | 428.6% | -10.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.05 | 0.01 | -0.44 | ||
| Avg | -1.27 | -0.58 | -0.50 | ||
| Low | -1.51 | -0.87 | -0.59 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.